This article is more than 5 years old. Information may no longer be current.
Boehringer Ingelheim, AbbVie plan global collaboration for psoriasis treatment candidate
Click Here to Manage Email Alerts
Boehringer Ingelheim announced plans to collaborate with AbbVie on developing immunology compounds for psoriasis treatment candidate BI 655066, according to a press release.
BI 655066 is an anti-IL-23 monoclonal biologic antibody in phase 3 clinical trial for safety and efficacy. In addition to psoriasis, the companies are assessing BI 655066 for Crohn’s disease, psoriatic arthritis and asthma. It is administered through subcutaneous injection within a 12-week treatment period. Phase 2 head-to-head trial results in patients with moderate-to-severe plaque psoriasis demonstrated that BI 655066 had greater efficacy over Stelara (ustekinumab, Janssen Biotech).
In addition, AbbVie will receive rights to BI 655064, an anti-CD-40 antibody in phase 1 development, and may elect to advance the clinical trial should BI 655064 meet its achievement standards.
“Our immunology [research and development] teams have successfully brought forward compounds that have the potential to transform the way immune diseases are treated,” Michel Pairet, MD, managing directors board member at Boehringer Ingelheim, said in the press release. “I believe the collaboration with AbbVie is the best way to ensure broad access for patients to BI 655066 and BI 655064.”